$MD
Pediatrix Medical Group, Inc. Stock $md

$md Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024016794 Filed on February 20, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$495.1M	$496.4M	$1.995B
YoY Change	0.83%	-3.39%	1.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$429.3M	$416.7M	$1.676B
YoY Change	1.91%	-0.23%	3.78%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$10.31M	$9.062M	$36.17M
YoY Change	15.13%	-0.81%	1.5%
% of Gross Profit
Operating Expenses	$479.2M	$457.4M	$1.987B
YoY Change	3.96%	-0.18%	10.45%
Operating Profit	$15.89M		$7.321M
YoY Change	-47.1%		-95.76%
Interest Expense	$10.60M	-$7.360M	$42.08M
YoY Change	2.01%	-10.4%	6.0%
% of Operating Profit	66.69%		574.72%
Other Income/Expense, Net	-$8.068M		-$55.68M
YoY Change	-13.52%		-39.03%
Pretax Income	$7.824M	-$138.9M	-$48.36M
YoY Change	-62.22%	-599.03%	-159.43%
Income Tax	$3.789M	-$14.56M	$12.05M
% Of Pretax Income	48.43%
Net Earnings	$4.035M	-$124.3M	-$60.41M
YoY Change	-71.6%	-519.05%	-191.07%
Net Earnings / Revenue	0.81%	-25.04%	-3.03%
Basic Earnings Per Share	$0.05		$0.73
Diluted Earnings Per Share	$0.05	-$1.51	$0.73
COMMON SHARES
Basic Shares Outstanding	84.12M	84.02M	82.20M
Diluted Shares Outstanding	83.28M		82.20M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.5M	$177.7M	$177.7M
YoY Change	12.29%	72.46%	72.46%
Cash & Equivalents	$7.998M	$73.26M	$73.26M
Short-Term Investments	$107.5M	$104.5M	$104.5M
Other Short-Term Assets	$9.578M	$12.31M	$25.83M
YoY Change	-20.64%	-7.19%	-8.2%
Inventory
Prepaid Expenses	$12.53M	$13.53M
Receivables	$283.7M	$272.3M	$272.3M
Other Receivables	$5.193M	$7.565M	$7.565M
Total Short-Term Assets	$426.5M	$483.5M	$483.5M
YoY Change	4.39%	12.96%	12.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$74.34M	$75.64M	$145.9M
YoY Change	1.94%	3.21%	4.08%
Goodwill	$1.393B	$1.380B
YoY Change	-9.06%	-9.8%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$83.07M	$82.17M	$185.0M
YoY Change	-30.41%	-33.29%	-19.24%
Total Long-Term Assets	$1.742B	$1.736B	$1.736B
YoY Change	-8.88%	-9.56%	-9.56%
TOTAL ASSETS
Total Short-Term Assets	$426.5M	$483.5M	$483.5M
Total Long-Term Assets	$1.742B	$1.736B	$1.736B
Total Assets	$2.168B	$2.220B	$2.220B
YoY Change	-6.55%	-5.45%	-5.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$31.64M	$34.59M	$34.59M
YoY Change	-10.46%	8.57%	8.57%
Accrued Expenses	$196.4M	$337.3M	$337.3M
YoY Change	-7.52%	-7.33%	-7.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.41M	$14.91M	$14.91M
YoY Change	10.02%	0.1%	0.1%
Total Short-Term Liabilities	$247.3M	$388.9M	$388.9M
YoY Change	-13.0%	-8.91%	-8.91%
LONG-TERM LIABILITIES
Long-Term Debt	$693.3M	$618.4M	$618.4M
YoY Change	-6.66%	-2.82%	-2.82%
Other Long-Term Liabilities	$33.49M	$30.55M	$329.1M
YoY Change	-11.03%	-22.48%	-8.4%
Total Long-Term Liabilities	$33.49M	$30.55M	$947.5M
YoY Change	-11.03%	-22.48%	-4.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$247.3M	$388.9M	$388.9M
Total Long-Term Liabilities	$33.49M	$30.55M	$947.5M
Total Liabilities	$1.312B	$1.371B	$1.371B
YoY Change	-6.97%	-5.87%	-5.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$145.4M	$149.5M
YoY Change	94.29%	-267.83%
Common Stock	$1.004B	$1.001B
YoY Change	1.62%	1.66%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$856.2M	$849.1M	$849.1M
YoY Change
Total Liabilities & Shareholders Equity	$2.168B	$2.220B	$2.220B
YoY Change	-6.55%	-5.45%	-5.45%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$4.035M	-$124.3M	-$60.41M
YoY Change	-71.6%	-519.05%	-191.07%
Depreciation, Depletion And Amortization	$10.31M	$9.062M	$36.17M
YoY Change	15.13%	-0.81%	1.5%
Cash From Operating Activities	-$125.2M	$69.25M	$137.3M
YoY Change	24.09%	-29.83%	-17.74%
INVESTING ACTIVITIES
Capital Expenditures	$5.330M	$9.044M	$33.33M
YoY Change	-23.85%	-0.15%	12.19%
Acquisitions	$8.167M		$6.667M
YoY Change	389.92%		-76.33%
Other Investing Activities	-$10.91M	-$3.380M	-$14.85M
YoY Change	150.7%	54.83%	-45.5%
Cash From Investing Activities	-$16.24M	-$12.42M	-$48.18M
YoY Change	43.07%	10.52%	-15.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$4.012M
YoY Change			-104.83%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	76.20M	-4.747M	-25.72M
YoY Change	-29.81%	-94.5%	-94.73%
NET CHANGE
Cash From Operating Activities	-125.2M	69.25M	137.3M
Cash From Investing Activities	-16.24M	-12.42M	-48.18M
Cash From Financing Activities	76.20M	-4.747M	-25.72M
Net Change In Cash	-65.26M	52.08M	63.43M
YoY Change	1663.78%	4405.1%	-116.8%
FREE CASH FLOW
Cash From Operating Activities	-$125.2M	$69.25M	$137.3M
Capital Expenditures	$5.330M	$9.044M	$33.33M
Free Cash Flow	-$130.6M	$60.21M	$104.0M
YoY Change	20.98%	-32.83%	-24.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0000893949
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.mednax.com/20231231#OperatingAndFinanceLeaseRightOfUseAssets
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.mednax.com/20231231#OperatingAndFinanceLeaseRightOfUseAssets
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OperatingLeaseLiabilityNoncurrent
CY2023	dei	Document Type DocumentType	10-K
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	12308000
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	13261000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	483454000
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-12111
CY2023	dei	Entity Registrant Name EntityRegistrantName	Pediatrix Medical Group, Inc.
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-3667538
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1301 Concord Terrace
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Sunrise
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33323
CY2023	dei	City Area Code CityAreaCode	954
CY2023	dei	Local Phone Number LocalPhoneNumber	384-0175
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2023	dei	Trading Symbol TradingSymbol	MD
CY2023	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	1176563587
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	84122979
CY2023	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2023	dei	Auditor Firm AuditorFirmId	238
CY2023	dei	Auditor Location AuditorLocation	Miami, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73258000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9824000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	104485000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	93239000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	272313000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	296787000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13525000
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14878000
CY2023Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	7565000
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	0
CY2022Q4	us-gaap	Assets Current AssetsCurrent	427989000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75639000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73290000
CY2023Q4	us-gaap	Goodwill Goodwill	1384166000
CY2022Q4	us-gaap	Goodwill Goodwill	1532092000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21240000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18491000
CY2023Q4	md	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	70294000
CY2022Q4	md	Operating And Finance Lease Right Of Use Assets OperatingAndFinanceLeaseRightOfUseAssets	66924000
CY2023Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	102852000
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	105925000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	82165000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	123176000
CY2023Q4	us-gaap	Assets Assets	2219810000
CY2022Q4	us-gaap	Assets Assets	2347887000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	350798000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	374225000
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	14913000
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	14898000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21076000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21589000
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2159000
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	16271000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	388946000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	426983000
CY2023Q4	us-gaap	Line Of Credit LineOfCredit	0
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	4000000
CY2023Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	618421000
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	632381000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47238000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44213000
CY2023Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	251284000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Noncurrent MalpracticeLossContingencyAccrualUndiscountedNoncurrent	275629000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	34308000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	33638000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30552000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39411000
CY2023Q4	us-gaap	Liabilities Liabilities	1370749000
CY2022Q4	us-gaap	Liabilities Liabilities	1456255000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84018023
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84018023
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82947132
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82947132
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	840000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	829000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	999906000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	983601000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2214000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3735000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	149471000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-89063000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	849061000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	891632000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2219810000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2347887000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1994640000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1972021000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1911191000
CY2023	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1448275000
CY2022	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1383319000
CY2021	md	Practice Salaries And Benefits PracticeSalariesAndBenefits	1297477000
CY2023	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	124800000
CY2022	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	121669000
CY2021	md	Practice Supplies And Other Operating Expenses PracticeSuppliesAndOtherOperatingExpenses	100472000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	227542000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	231397000
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	263357000
CY2023	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2021	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	-7280000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36171000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35636000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32147000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	2219000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	27312000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	22100000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	148312000
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2023	us-gaap	Operating Expenses OperatingExpenses	1987319000
CY2022	us-gaap	Operating Expenses OperatingExpenses	1799333000
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1521000
CY2022	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-5051000
CY2021	us-gaap	Operating Expenses OperatingExpenses	1708273000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	7321000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	172688000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	202918000
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	4338000
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	3671000
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	13652000
CY2023	us-gaap	Interest Expense InterestExpense	42075000
CY2022	us-gaap	Interest Expense InterestExpense	39695000
CY2021	us-gaap	Interest Expense InterestExpense	68722000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	20000000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-57016000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-14532000
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	2057000
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1722000
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	1912000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-55680000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-91318000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-67690000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48359000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	81370000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	135228000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12049000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18806000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27241000
CY2023	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-60408000
CY2022	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	62564000
CY2021	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	107987000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3767000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	22950000
CY2023	us-gaap	Profit Loss ProfitLoss	-60408000
CY2022	us-gaap	Profit Loss ProfitLoss	66331000
CY2021	us-gaap	Profit Loss ProfitLoss	130937000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60408000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	66335000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	130964000
CY2023	md	Net Of Tax Unrealized Holding Gain Loss On Investments NetOfTaxUnrealizedHoldingGainLossOnInvestments	527000
CY2022	md	Net Of Tax Unrealized Holding Gain Loss On Investments NetOfTaxUnrealizedHoldingGainLossOnInvestments	1694000
CY2021	md	Net Of Tax Unrealized Holding Gain Loss On Investments NetOfTaxUnrealizedHoldingGainLossOnInvestments	742000
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-2213000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58887000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	61284000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	128751000
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.73
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.75
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.27
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.73
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.74
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.26
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.04
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.27
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.05
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.27
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.73
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.79
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.54
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.79
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82201000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83467000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84832000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82201000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84121000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85828000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	747717000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	130964000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-27000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-2213000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6852000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18118000
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	4719000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	896692000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	66335000
CY2022	md	Dissolution Of And Net Income Loss Attributable To Noncontrolling Interest DissolutionOfAndNetIncomeLossAttributableToNoncontrollingInterest	-206000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-5051000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5396000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16977000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	88511000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	891632000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60408000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	1521000
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4912000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12323000
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	919000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	849061000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60408000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	66335000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	130964000
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	3767000
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	22950000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	36171000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35636000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	32147000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1239000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1765000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	4335000
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	168312000
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-57016000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-14532000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	12323000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	16127000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	18968000
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3239000
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22771000
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-31239000
CY2023	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2022	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	0
CY2021	us-gaap	Gain Loss On Sale Of Properties GainLossOnSaleOfProperties	-7280000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3167000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-144000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2350000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-26276000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5543000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	72731000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-514000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-15928000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-41530000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-22851000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-17196000
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-9799000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11921000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	420000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	21326000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-21677000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	18225000
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2285000
CY2023	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	837000
CY2022	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	5600000
CY2021	us-gaap	Increase Decrease In Liability For Claims And Claims Adjustment Expense Reserve IncreaseDecreaseInLiabilityForClaimsAndClaimsAdjustmentExpenseReserve	1523000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-28508000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-19999000
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-22529000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	146081000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	182312000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	113760000
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-8756000
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-15371000
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-37023000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	137325000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	166941000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	76737000
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	6667000
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	28167000
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	29930000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	31893000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17346000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	15052000
CY2023	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	22905000
CY2022	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	16889000
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	16496000
CY2023	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	33328000
CY2022	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	29708000
CY2021	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	32249000
CY2023	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	0
CY2022	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	0
CY2021	us-gaap	Proceeds From Sale Of Buildings ProceedsFromSaleOfBuildings	24728000
CY2023	md	Strategic Investments StrategicInvestments	0
CY2022	md	Strategic Investments StrategicInvestments	0
CY2021	md	Strategic Investments StrategicInvestments	20000000
CY2023	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	807000
CY2022	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	1378000
CY2021	us-gaap	Proceeds From Sale Of Other Productive Assets ProceedsFromSaleOfOtherProductiveAssets	584000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-48176000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-56954000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-55423000
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0
CY2021	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	2350000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48176000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-56954000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-53073000
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	470000000
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	830000000
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	474000000
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	826000000
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0
CY2023	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0
CY2022	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1046880000
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	759848000
CY2023	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0
CY2022	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	650000000
CY2021	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0
CY2023	md	Payments To Term Loan PaymentsToTermLoan	12500000
CY2022	md	Payments To Term Loan PaymentsToTermLoan	9375000
CY2021	md	Payments To Term Loan PaymentsToTermLoan	0
CY2023	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8621000
CY2021	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1817000
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0
CY2021	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	189000
CY2023	md	Repayments Of Long Term Capital Lease Obligation RepaymentsOfLongTermCapitalLeaseObligation	2618000
CY2022	md	Repayments Of Long Term Capital Lease Obligation RepaymentsOfLongTermCapitalLeaseObligation	2916000
CY2021	md	Repayments Of Long Term Capital Lease Obligation RepaymentsOfLongTermCapitalLeaseObligation	2809000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4912000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5396000
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6853000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	919000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	88511000
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	4719000
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-8773000
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	9353000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	596000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-25715000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-487554000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-760116000
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2021	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-25715000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-487554000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-760116000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63434000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-377567000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-736452000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9824000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	387391000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1123843000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73258000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9824000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	387391000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	42278000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	116235000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	86537000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30835000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	26908000
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	54728000
CY2023	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	132000
CY2022	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	282000
CY2021	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	6762000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2874000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2589000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2300000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. General:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On July 1, 2022, effective after the close of the market, the Company changed its corporate name from “Mednax, Inc.” to “Pediatrix Medical Group, Inc.” signifying the Company's return to its core focus in caring for women, babies and children. The Company’s common stock continues to trade on the New York Stock Exchange under the ticker symbol “MD.”</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The principal business activity of Pediatrix Medical Group, Inc. (“Pediatrix” or the “Company”) and its subsidiaries is to provide neonatal, maternal-fetal and other pediatric subspecialty physician services. The Company has contracts with affiliated business corporations or professional associations, limited liability companies and partnerships (“affiliated professional contractors”), which are separate legal entities that provide physician services in certain states and Puerto Rico. The Company ceased providing services in Puerto Rico effective December 31, 2022. The Company and its affiliated professional contractors also have contracts with hospitals and other healthcare facilities to provide physician services, which include (i) fee-for-service contracts, whereby hospitals and other customers agree, in exchange for the Company’s services, to authorize the Company and its healthcare professionals to bill and collect the charges for medical services rendered by the Company’s affiliated healthcare professionals, and (ii) administrative fee contracts, whereby the Company is assured a minimum revenue level.</span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accounting Estimates and Assumptions</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions are</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">involved </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">in the calculation of the Company's allowance for contractual adjustments and uncollectibles on accounts receivable, liabilities for self-insured amounts and claims incurred but not reported related to the Company’s professional liability risks and the fair value of goodwill. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	218354000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	245508000
CY2023	md	Cash And Cash Equivalents Maturity Description CashAndCashEquivalentsMaturityDescription	90
CY2023Q4	us-gaap	Asset Impairment Charges AssetImpairmentCharges	20000000
CY2023	md	Business Combination Contingent Consideration Arrangements Time Period BusinessCombinationContingentConsiderationArrangementsTimePeriod	P5Y
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	148300000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	142715000
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	0
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	93239000
CY2023Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1379213000
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1548492000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1106900000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1251705000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	272313000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	296787000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1994640000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1972021000
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	1911191000
CY2023	md	Percentage Of Net Patient Service Revenue By Type Of Payor PercentageOfNetPatientServiceRevenueByTypeOfPayor	1
CY2022	md	Percentage Of Net Patient Service Revenue By Type Of Payor PercentageOfNetPatientServiceRevenueByTypeOfPayor	1
CY2021	md	Percentage Of Net Patient Service Revenue By Type Of Payor PercentageOfNetPatientServiceRevenueByTypeOfPayor	1
CY2023Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	8286000
CY2022Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	8286000
CY2023Q4	us-gaap	Land Land	2032000
CY2022Q4	us-gaap	Land Land	2032000
CY2023Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	208036000
CY2022Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	235190000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	172218000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75639000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73290000
CY2023	us-gaap	Depreciation Depreciation	28100000
CY2022	us-gaap	Depreciation Depreciation	26700000
CY2021	us-gaap	Depreciation Depreciation	21600000
CY2023Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	400000
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	4500000
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	100000
CY2022Q4	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	26700000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangibles BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles	2300000
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	2200000
CY2023Q4	us-gaap	Goodwill Goodwill	1380000000
CY2022Q4	us-gaap	Goodwill Goodwill	1530000000
CY2023	md	Good Will Impairment Loss Excluding Deferred Tax Assets Charge GoodWillImpairmentLossExcludingDeferredTaxAssetsCharge	125000000
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	23300000
CY2023	md	Incremental Non Cash Charge IncrementalNonCashCharge	23300000
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	148300000
CY2023	md	Change In Rate Of Control Premium ChangeInRateOfControlPremium	0.01
CY2023	md	Change In Non Cash Impairment Charges ChangeInNonCashImpairmentCharges	9000000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	114168000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	92928000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	21240000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	110020000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	91529000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	18491000
CY2023	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	4500000
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P10Y
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5600000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6400000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8000000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	5751000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3815000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2928000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1621000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1394000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	34588000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	31857000
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	193112000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	197831000
CY2023Q4	md	Accrued Payroll Taxes And Benefits Current AccruedPayrollTaxesAndBenefitsCurrent	36545000
CY2022Q4	md	Accrued Payroll Taxes And Benefits Current AccruedPayrollTaxesAndBenefitsCurrent	34983000
CY2023Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	32039000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	32232000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8262000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	8921000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	46252000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	68401000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	350798000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	374225000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	61693000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55796000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21076000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21589000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47238000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	44213000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.055
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	23200000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	22293000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	5854000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6640000
CY2023	md	Operating Leases Other Costs OperatingLeasesOtherCosts	3613000
CY2022	md	Operating Leases Other Costs OperatingLeasesOtherCosts	4218000
CY2023	us-gaap	Lease Cost LeaseCost	32667000
CY2022	us-gaap	Lease Cost LeaseCost	33151000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	35747000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	37549000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	22141000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	17421000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12436000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8906000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	5501000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	10142000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	76547000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8233000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	68314000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	21076000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	47238000
CY2023Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	283300000
CY2022Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted MalpracticeLossContingencyAccrualUndiscounted	307900000
CY2023Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	178100000
CY2022Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	215500000
CY2023Q4	md	Accrued Professional Liability AccruedProfessionalLiability	105200000
CY2022Q4	md	Accrued Professional Liability AccruedProfessionalLiability	92400000
CY2023Q4	us-gaap	Malpractice Loss Contingency Accrual Undiscounted Current MalpracticeLossContingencyAccrualUndiscountedCurrent	32000000
CY2023Q4	us-gaap	Insurance Settlements Receivable InsuranceSettlementsReceivable	33200000
CY2022Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	199561000
CY2021Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	190127000
CY2020Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	174803000
CY2023	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	-5510000
CY2022	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	-2692000
CY2021	md	Accrued Professional Liabilities Assumed Through Acquisition AccruedProfessionalLiabilitiesAssumedThroughAcquisition	-2299000
CY2023	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	55144000
CY2022	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	53180000
CY2021	md	Provision Adjustment For Losses Related To Current Year ProvisionAdjustmentForLossesRelatedToCurrentYear	56016000
CY2023	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-7551000
CY2022	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-4056000
CY2021	md	Provision Adjustment For Losses Related To Prior Year ProvisionAdjustmentForLossesRelatedToPriorYear	-14231000
CY2023	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	47593000
CY2022	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	49124000
CY2021	md	Malpractice Loss Contingency Provision For Losses MalpracticeLossContingencyProvisionForLosses	41785000
CY2023	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	97000
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	73000
CY2021	us-gaap	Malpractice Loss Contingency Claims Incurred In Period MalpracticeLossContingencyClaimsIncurredInPeriod	59000
CY2023	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	38951000
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	36925000
CY2021	us-gaap	Malpractice Loss Contingency Claims Incurred In Prior Periods MalpracticeLossContingencyClaimsIncurredInPriorPeriods	24103000
CY2023	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	39048000
CY2022	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	36998000
CY2021	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	24162000
CY2023Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	202596000
CY2022Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	199561000
CY2021Q4	md	Malpractice Loss Contingency Accrual Undiscounted Excluding Retained Professional Liabilities Related To Anesthesiology And Radiology Operations MalpracticeLossContingencyAccrualUndiscountedExcludingRetainedProfessionalLiabilitiesRelatedToAnesthesiologyAndRadiologyOperations	190127000
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05375
CY2023	us-gaap	Debt Instrument Frequency Of Periodic Payment DebtInstrumentFrequencyOfPeriodicPayment	payable semi-annually in arrears on February 15 and August 15, beginning on August 15, 2022
CY2023	us-gaap	Debt Instrument Description DebtInstrumentDescription	Notes are guaranteed on an unsecured senior basis by the same subsidiaries and affiliated professional contractors that guarantee the Amended Credit Agreement (as defined below). The indenture under which the 2030 Notes are issued, among other things, limits the Company's ability to (1) incur liens and (2) enter into sale and lease-back transactions, and also limits the Company's ability to merge or dispose of all or substantially all of its assets, in all cases, subject to a number of customary exceptions
CY2023Q4	md	Purchase Price PurchasePrice	1.01
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	622200000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	637200000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	628125000
CY2023Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	5919000
CY2023Q4	md	Long Term Debt Net LongTermDebtNet	622206000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	644625000
CY2022Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	7385000
CY2022Q4	md	Long Term Debt Net LongTermDebtNet	637240000
CY2023Q4	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	450000000
CY2022	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	February 2022
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	9241000
CY2022Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	11128000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2413000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2398000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	6828000
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	8730000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	8040000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	38877000
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	41592000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1467000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-19679000
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-20373000
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	9507000
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	19198000
CY2021	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	21219000
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	770000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2700000
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	16888000
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1772000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3092000
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-10866000
CY2023	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2542000
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	-392000
CY2021	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	6022000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	12049000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18806000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	27241000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.249
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.231
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.201
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Impairment Losses IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses	17800000
CY2021	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	10800000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0279
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0153
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0472
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0443
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0148
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.0342
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0398
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0135
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0077
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0067
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0328
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0108
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1382
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0172
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0026
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.2667
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0048
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0069
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0046
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.0797
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.2492
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2311
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2014
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	139998000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	152526000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	59218000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves	66969000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2800000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4900000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2400000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3022000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3694000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34739000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	28773000
CY2023Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	422809000
CY2022Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	422793000
CY2023Q4	md	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	19133000
CY2022Q4	md	Deferred Tax Assets Operating Lease Assets DeferredTaxAssetsOperatingLeaseAssets	19096000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2056000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2481000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5520000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	256000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	686495000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	696588000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	435940000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	429260000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	250555000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	267328000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	162538000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	176398000
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	17342000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	16510000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2131000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2133000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	182011000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	195041000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	68544000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	72287000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	68500000
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	72300000
CY2023	md	Increase Decrease In Deferred Tax Assets IncreaseDecreaseInDeferredTaxAssets	3800000
CY2023	md	Increase Decrease In Uncollectible Account Related To Deferred Tax Assets IncreaseDecreaseInUncollectibleAccountRelatedToDeferredTaxAssets	12500000
CY2023	md	Increase Decrease In Reserves And Accruals IncreaseDecreaseInReservesAndAccruals	7800000
CY2023	md	Increase Decrease In Valuation Allowance IncreaseDecreaseInValuationAllowance	6700000
CY2023	md	Increase Decrease In Operating And Other Loss Carryforwards IncreaseDecreaseInOperatingAndOtherLossCarryforwards	5900000
CY2023	md	Increase Decrease In Other Items IncreaseDecreaseInOtherItems	5200000
CY2023	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	13900000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6700000
CY2023	md	Income Tax Expense For Excess Tax Deficiencies IncomeTaxExpenseForExcessTaxDeficiencies	1900000
CY2022	md	Income Tax Expense For Excess Tax Deficiencies IncomeTaxExpenseForExcessTaxDeficiencies	1100000
CY2021	md	Income Tax Expense For Excess Tax Deficiencies IncomeTaxExpenseForExcessTaxDeficiencies	1000000
CY2023Q4	md	Capital Loss Carryforwards CapitalLossCarryforwards	1710000000
CY2023	md	Net Operating Loss Carry Forwards Expiration Date NetOperatingLossCarryForwardsExpirationDate	2025
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	56400000
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	46700000
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	61700000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	18300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	38100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2838000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4928000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6168000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	70000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	379000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	200000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	800000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	900000
CY2023	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	659000
CY2022	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	3269000
CY2021	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	2140000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2449000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2838000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4928000
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	800000
CY2023	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	200000
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	300000
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	400000
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	300000
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	200000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82201000
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	83467000
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	84832000
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	654000
CY2021	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	996000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82201000
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	84121000
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	85828000
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1115000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	406000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11000
CY2023	md	Incremental Shares Not Included Due To Anti Dilutive Effect IncrementalSharesNotIncludedDueToAntiDilutiveEffect	400000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12300000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14400000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19000000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1195397
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	23.32
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	820101
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.25
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	239653
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	22.61
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	418756
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	22.91
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1357089
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	18.69
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	9600
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	19100000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	25100000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.64
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	25.17
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	887731
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.91
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	887731
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	16.91
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2023	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
CY2018Q3	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	500000000
CY2018Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	4600000
CY2023Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	61000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	900000
CY2022Q4	us-gaap	Stock Repurchase Program Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased	4500000
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	88500000
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	24100000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	22600000
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	21000000
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1251705000
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1091310000
CY2020Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	791842000
CY2023	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	6069245000
CY2022	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	5921519000
CY2021	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	5436786000
CY2023	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-6214050000
CY2022	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-5761124000
CY2021	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-5137318000
CY2023Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1106900000
CY2022Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1251705000
CY2021Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	1091310000

Files In Submission

Name	View Source	Status
0000950170-24-016794-index-headers.html	Edgar Link	pending
0000950170-24-016794-index.html	Edgar Link	pending
0000950170-24-016794.txt	Edgar Link	pending
0000950170-24-016794-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img259372340_0.jpg	Edgar Link	pending
md-20231231.htm	Edgar Link	pending
md-20231231.xsd	Edgar Link	pending
md-ex10_15.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
md-20231231_htm.xml	Edgar Link	completed
md-ex10_17.htm	Edgar Link	pending
md-ex21_1.htm	Edgar Link	pending
md-ex23_1.htm	Edgar Link	pending
md-ex31_1.htm	Edgar Link	pending
md-ex31_2.htm	Edgar Link	pending
md-ex32.htm	Edgar Link	pending
md-ex97_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MD
Pediatrix Medical Group, Inc. Stock $md

2024 Q1 Form 10-K Financial Statement

#000095017024016794 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD Pediatrix Medical Group, Inc. Stock $md

2024 Q1 Form 10-K Financial Statement

#000095017024016794 Filed on February 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MD
Pediatrix Medical Group, Inc. Stock $md